期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Research Progress in the Use of Drugs for Breast Cancer Targeted Therapy 被引量：22

Research Progress in the Use of Drugs for Breast Cancer Targeted Therapy
下载PDF
导出
摘要 In recent years,many significant advances have been made on molecular target therapy to aim directly at epidermal growth factor receptors and vascular endothelial growth factor in breast cancers.Clinical studies of such agents as trastuzumab,lapatinib,erlotinib and bevacituzumab have been widely conducted.This paper will review the recent research progress related to targeted therapy. In recent years,many significant advances have been made on molecular target therapy to aim directly at epidermal growth factor receptors and vascular endothelial growth factor in breast cancers.Clinical studies of such agents as trastuzumab,lapatinib,erlotinib and bevacituzumab have been widely conducted.This paper will review the recent research progress related to targeted therapy.
作者 Shun ＇e Yang Bing Zhao
机构地区 Department of Medical Oncology
出处 《Chinese Journal of Clinical Oncology》 CSCD 2008年第5期320-325,共6页 中国肿瘤临床（英文版）
关键词 breast cancer targeted therapy human epidermalgrowth factor receptors vascular endothelial growth factor. 乳癌 分子靶点治疗 表皮因子生长接受器 肿瘤学
分类号 R273 [医药卫生—中西医结合]
  • 相关文献

参考文献11

  • 1Keiko Furukawa,Yoshinori Ito,Shunji Takahashi,Masataka Sawaki,Nobuyuki Mizunuma,Noboru Horikoshi,Fujio Kasumi,Futoshi Akiyama,Goi Sakamoto,Kiyonori Furukawa,Takashi Tajiri,Kiyohiko Hatake.Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience[J].Breast Cancer.2006(4)
  • 2Wen XF,Yang G,Mao W,et al.HER-2 signaling modu-lates the equilibrium between pro-and antiangiogenicfactors via distinct pathways:implications for HER-2-targeted antibody therapy[].Oncegene.2006
  • 3Arnould L,GellyM,Penault-Llorca F,et al.Trastuzum-ab-based treatment ofHER-2-positive breast cancer:an antibody-dependent cellular cytotoxicity mecha-nism[].British Journal of Cancer.2006
  • 4Furukawa K,Ito Y,Takahashi S,et al.Efficacy andsafety of combined trastuzumab and Paclitaxel ther-apy as a second-line treatment in women with meta-static breast cancer:a single institutional experience[].Breast Cancer.2006
  • 5Ciardiello F,Troiani T,Caputo F,et al.Phase II studyof gefitinib in combination with docetaxel as first-linetherapy in metastatic breast cancer[].British Journal of Cancer.2006
  • 6Karen E,Lackey KE.Lessons from the drug discov-ery of lapatinib,a dual ErbB1/2 tyrosine kinase inhibi-tor[].Current Topics in Medicinal Chemistry.2006
  • 7Wood ER,Truesdale AT,McDonald OB,et al.A uniquestructure for epidermal growth receptor bound toGW572016(lapatinib):Relationships among proteinconformation,inhibitor off-rate,and receptor activityin tumor cells[].Cancer Research.2004
  • 8Blackwell KL,Kaplan EH,Franco SX,et al.A phase II,open-label,multicenter study of GW572016 in pa-tients with trastuzumab-refractory metastatic breastcancer[].Proceedings of the American Society of Clinical Oncology.2004
  • 9Gomez HL,Chavez MA,Doval DC,et al.Results froma phase II randomized study of lapatinib as firstlinetreatment for patients with ErbB2-amplified advancedor metastatic breast cancer[].Breast Cancer Research and Treatment.2006
  • 10Spector NL,Blackwell K,Hurley J,et al.EGF103009,aphase II trial of lapatinib monotherapy in patients withrelapsed/refractory inflammatory breast cancer(IBC):Clinical activity and biologic predictors of response[].Proceedings of the American Society of Clinical Oncology.2006

同被引文献87

引证文献22

二级引证文献173

Chinese Journal of Clinical Oncology
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部